Industry calls Union Budget 2026 a defining moment for India’s biopharma future
Industry stakeholders view the Union Budget 2026 as a pivotal inflection point in India’s life sciences journey. With the launch…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Biocon Biologics secures global manufacturing and commercial rights for Hulio
Agreement with Fujifilm Kyowa Kirin Biologics covers biosimilar Adalimumab
Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation
Agreement enables Europe launch of Vevzuo and Evfraxy from December 2025
Health Canada grants NOC for Biocon Biologics’ Yesintek and Yesintek I.V
Biocon Biologics receives Canadian approval for ustekinumab biosimilars for autoimmune conditions
Biocon Biologics expands partnership with Civica to launch Insulin Glargine in the US
Biocon Biologics and Civica collaboration aims to increase access to affordable insulin in the United States
Panel Discussion: Bengaluru: An emerging global innovation gateway?
Bengaluru, known globally as India’s IT capital, is now fast emerging as a powerful hub for pharma and life sciences. With its…
Biocon Biologics clears path for U.S. launch of denosumab biosimilars Bosaya and Aukelso
Settlement with Amgen enables commercialisation of Bosaya and Aukelso in the United States from October 1, 2025
Biocon Biologics appoints Deepali Naair as head, corporate communications
Seema Ahuja will post her retirement from Biocon Biologics move into a non-business facing role in Biocon Chairperson’s office
Biocon Biologics gains USFDA approval for Kirsty, Interchangeable Rapid-Acting Insulin Aspart
KIRSTY will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and…
Biocon Biologics gains UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
Vevzuo is authorised for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord…